治疗慢性阻塞性肺部疾病的Ivacaftor - 从第二期随机对照试验的结果,随机对照试验
Kadambari Vijaykumar1, George M Solomon2, Jennifer Guimbellot3
1The University of Alabama at Birmingham, Birmingham, Alabama, United States.
American journal of respiratory and critical care medicine
|September 24, 2024
概括
伊瓦卡夫托对COPD患者来说是安全的,但没有改善CFTR活性或粘液清除. 需要进一步的研究来确定COPD治疗中CFTR增强剂的最佳剂量.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 慢性阻塞性肺病 (COPD) 患者表现出获得的囊性纤维化通过膜导电调节器 (CFTR) 功能障碍.
- CFTR调节剂对COPD具有潜在的治疗益处,但其有效性和对粘膜细胞清除的影响的证据仍然不确.
- 这项研究调查了ivacaftor在COPD患者中的安全性,耐受性和机制.
研究的目的:
- 评估IVACAFTOR在中度至重度COPD患者中的安全性和耐受性.
- 探索 ivacaftor 在治疗 COPD 的潜在机制.
- 评估伊瓦卡夫托对CFTR活性和COPD临床结果的影响.
主要方法:
- 一个2期,随机,双盲,安慰剂对照试验,涉及40名中度至重度COPD患者.
- 患者接受了 ivacaftor (N=30) 或安慰剂 (N=10) 150mg两次在12周内.
- 主要终点包括安全性和药理动力学 (PK);次要终点评估了CFTR活性和临床结果.
主要成果:
- 伊瓦卡夫托尔证明了安全性和耐受性,在不同组之间具有可比的不良事件率. 腹是 ivacaftor 组中最常见的副作用.
- 药物动力学分析显示,平均AUC12是囊性纤维化 (CF) 患者在相同剂量下报告的AUC12的72%.
- 伊瓦卡夫托尔治疗没有显著改善汗液化物,整个肺膜清除,肺功能或呼吸系统症状.
结论:
- 伊瓦卡夫托在COPD患者中安全且耐受性良好,但没有增强CFTR活性或粘液清除.
- 与CF相比,COPD获得的血清度较低,野生型CFTR与G551D的调制不同,需要进行进一步的剂量检测研究.
- 在COPD中优化CFTR增强剂的疗效需要对适当的剂量和患者选择进行额外的研究.
相关概念视频
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
01:22Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
01:26COPD: Management Using Bronchodilators and Corticosteroids
186
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
186